title: The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA).
abstract: The aim of this study was to investigate the role of IL-12 in patients with RA. IL-12 (p70) and its associated cytokines were measured in sera and synovial fluid (SF) using an enzyme-linked immunosorbent method. Seven American College of Rheumatology (ACR) core set measures as well as IL-12 levels were sequentially monitored at the commencement and 4 months after treatment with a low-dose steroid and disease-modifying anti-rheumatic drugs (DMARDs). In sera, 64 (42.2%) of 152 RA patients had detectable concentrations of IL-12 (p70), whereas one (1.4%) of 69 osteoarthritis (OA) patients and five (10%) of 50 healthy controls had detectable IL-12 (P < 0.001). The median level of circulating IL-12 was also higher in RA patients (P < 0.001). In SF, the number of patients with detectable IL-12 and the median IL-12 levels were significantly higher in RA patients (n = 53) than in OA patients (n = 22). In paired samples (n = 53) of sera and SF from RA patients, IL-12 levels were higher in the SF than in sera (P < 0.001). Patients with detectable IL-12 (n = 51) in sera had higher tender joint scores (P = 0.003), swollen joint scores (P < 0.001) and C-reactive protein (CRP; P = 0.036), than those without (n = 55). Four months after treatment with DMARDs, the improved group showed a larger IL-12 decrease than the non-improved group (P = 0.017). The levels of IL-12 correlated positively with those of IL-2, interferon-gamma, IL-6, and tumour necrosis factor-alpha, but were correlated inversely with those of IL-10. Our results demonstrate that IL-12 levels reflect RA disease activity and that IL-12 is involved in the production of proinflammatory cytokines. An IL-12 blockade could be useful for the treatment of RA.
authors.affiliation: Centre for Rheumatic Diseases, Catholic Research Institute of Medical Science, Kang-Nam St Mary's Hospital, Department of Internal Medicine, Catholic University of Korea, Seoul, Korea.
authors.forename: W
authors.initials: W
authors.lastname: Kim
authors.forename: S
authors.initials: S
authors.lastname: Min
authors.forename: M
authors.initials: M
authors.lastname: Cho
authors.forename: J
authors.initials: J
authors.lastname: Youn
authors.forename: J
authors.initials: J
authors.lastname: Min
authors.forename: S
authors.initials: S
authors.lastname: Lee
authors.forename: S
authors.initials: S
authors.lastname: Park
authors.forename: C
authors.initials: C
authors.lastname: Cho
authors.forename: H
authors.initials: H
authors.lastname: Kim
authors.forename: W U
authors.initials: WU
authors.lastname: Kim
authors.forename: S Y
authors.initials: SY
authors.lastname: Min
authors.forename: M L
authors.initials: ML
authors.lastname: Cho
authors.forename: D J
authors.initials: DJ
authors.lastname: Min
authors.forename: S H
authors.initials: SH
authors.lastname: Lee
authors.forename: S H
authors.initials: SH
authors.lastname: Park
authors.forename: C S
authors.initials: CS
authors.lastname: Cho
authors.forename: H Y
authors.initials: HY
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood / Q000378:metabolism; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000097:blood / Q000378:metabolism*; D018664:Interleukin-12 / Q000037:antagonists & inhibitors / Q000097:blood / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000276:immunology; D013582:Synovial Fluid / Q000276:immunology
chemical_list: D018501:Antirheumatic Agents; D016207:Cytokines; D018836:Inflammation Mediators; D018664:Interleukin-12